feedback

Course Director

Nicolaus Kröger, MD
Nicolaus Kröger, MD

University Hospital Hamburg-Eppendorf
Hamburg, Germany

Faculty

Vikas Gupta
Vikas Gupta, MD, FRCP, FRCPath

Princess Margaret Cancer Center
Toronto, Ontario, Canada

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Apr-05
Expiration Date:2018-Apr-04
Estimated Time for Completion:60 mintues
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Hematopoietic stem cell transplantation (HCT) is a potentially curative treatment option for myelofibrosis (MF); however, many patients have traditionally not been eligible for transplant. Recent developments in therapy for MF—particularly the emergence of JAK inhibitors—have increased the number of treatment options for patients with MF. These advances have also raised several questions with implications for HCT, including whether transplant-based treatment can be used in conjunction with JAK inhibitors and other emerging treatments.

In this activity based on the 2017 BMT Tandem Meetings in Orlando, Florida leading experts in MF offer clinical insights on the evolving role of HCT in the modern JAK inhibitor–based treatment era for patients with MF and discuss the practical considerations of eligibility, the impact of JAK inhibitor therapy on post-transplant outcomes, and the optimal combination and sequencing of these two modalities in appropriate patient candidates.

Upon completion of this activity, participants should be better able to:

  • Describe the evolving role of allogeneic HCT in the modern treatment paradigm for patients with myelofibrosis
  • Discuss efficacy and safety data for the use of JAK inhibitors in the HCT setting for patients with myelofibrosis
  • Select patients with myelofibrosis who are candidates to receive JAK inhibitor therapy in conjunction with allogeneic HCT

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients with MF.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 05, 2017 - April 04, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Nicolaus Kröger, MD
Professor of Medicine
Director
Department of Stem Cell Transplantation
University Hospital Hamburg-Eppendorf
Hamburg, Germany

Nicolaus Kröger, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Neovii Pharmaceuticals AG and Novartis AG.
Speakers Bureau participant with Neovii Pharmaceuticals AG and Novartis AG.

Faculty

Vikas Gupta, MD, FRCP, FRCPath
Director, The Elizabeth and Tony Comper MPN Program
Princess Margaret Cancer Center
Toronto, Ontario, Canada

Vikas Gupta, MD, FRCP, FRCPath, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Incyte Corporation and Novartis Pharmaceuticals Canada inc.
Speakers Bureau participant with Incyte Corporation and Novartis Pharmaceuticals Canada inc.
Advisory Board for Incyte Corporation and Novartis Pharmaceuticals Canada inc.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership

This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Incyte Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.


Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.